NCT03936894View on ClinicalTrials.gov

Single Escalating Dose Pilot Trial of Canakinumab (ILARIS®) in Duchenne Muscular Dystrophy

PHASE1/PHASE2UnknownINTERVENTIONAL

Enrollment

3

Participants

Timeline

Start Date

May 1, 2019

Primary Completion Date

April 30, 2024

Study Completion Date

April 30, 2024

Conditions

Duchenne Muscular Dystrophy

Interventions

DRUG

Canakinumab Injection [Ilaris]

Subject receives subcutaneous injection of canakinumab 2 mg/ kg or 4 mg/kg

Trial Locations (1)

20010

Children's National Medical Center, Washington D.C.

Sponsors

Lead Sponsor

Children's National Research Institute

All Listed Sponsors

collaborator

Foundation to Eradicate Duchenne

UNKNOWN

lead

Children's National Research Institute

OTHER